Regiocontrolled functionalization of 2,3-dihalogenoimidazo[1,2-a]pyridines by Suzuki and Sonogashira cross-coupling reactions

Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry. This journal is The Royal Society of Chemistry 217 Regiocontrolled functionalization of 2,3-dihalogenoimidazo[1,2-a]pyridines by Suzuki and Sonogashira cross-coupling reactions P.-O. Delaye, a M. Pénichon, a H. Allouchi, a C. Enguehard-Gueiffier b and A. Gueiffier b a) UMR IRA 1282 Infectiologie et Santé Publique, Recherche et Innovation en Chimie Médicinale, Université François Rabelais, 31 avenue Monge, 372 Tours, France. b) UMR ISERM 169 utrition, Croissance et cancer, Université François Rabelais, 31 avenue Monge, 372 Tours, France. SUPPORTIG IFORMATIOS 1) Generals considerations 2) Characterization data for products 3) Copies of MR spectra for products 1

General considerations All reagents were used directly as obtained commercially. Thin-layer chromatography (TLC) were performed using Merk silica gel 6F 254 plates. Column chromatography were preformed using Merck Geduran Si 6 (4-63µm) silica. Melting points were determined on a capillary apparatus (Stuart, Staffordshire, United Kingdom) and are uncorrected. Microwave heating was performed using CEM Explorer SP 12 S class apparatus (max power 3W). MR experiments were performed at 3 mhz ( 1 H) and 75 mhz ( 13 C) on a Bruker-Avance 3 MHz spectrometer. Assignment of carbons noted C* may be interchanged. Mass spectra were determined on a Hewlett Packard 5988A spectrometer or on a Shimadzu QP 21 spectrometer by direct inlet at 7 ev. MR data for compounds 2a 1, 2b 2, 3a 3, 3b 4, 3d 5, 3f 4 and 6a 6 were previously described in literature. 2,3-diodoimidazo[1,2-a]pyridine (1a) To a stirred solution of 2-iodoimidazo[1,2-a]pyridine (1.22g, 5mmol, 1eq) in CH 3 C (2mL) was added IS (1.24g, 5.5mmol, 1.1eq) in one portion at room temperature. A white solid precipitated quickly. After 3h at room temperature the reaction was quenched with 3mL of water and extracted thrice with 3mL of CH 2 Cl 2. The combined organic phases were washed with 5mL of a 2 S 2 O 3 aqueous saturated solution, dried on a 2 SO 4 and evaporated to dryness. The pale yellow solid obtained (1.7g, 4,6mmol, yield: 92%) is used without further purification. 1 H MR (CDCl 3 ) δ: 8.3 (d, 1H, J = 9Hz, H-5), 7.54 (d, 1H, J = 9Hz, H- 8), 7.2 (ddd, 1H, J = 9.Hz, 6.9Hz, 1.Hz H-7), 6.89 (td, 1H, J = 9.Hz,.6Hz, H-6). 13 C MR (CDCl 3 ) δ: 149.4 (C-8a), 127. (C-5), 125.7 (C-7), 117.2 (C-8), 113.9 (C-6), 14.6 (C-2), 73. (C-3). m.p.: 114-118 C. HRMS (ESI): m/z calculated for C 7 H 4 I 2 2 [M+H] + : 37.85366, found: 37.85389. 2-iodo-3-bromoimidazo[1,2-a]pyridine (1b) To a stirred solution of 2-iodoimidazo[1,2-a]pyridine (1.75g, 7.2mmol, 1eq) in CH 3 C (3mL) was added BS (1.4g, 7.9mmol, 1.1eq) in one portion at room temperature. A white solid precipitated quickly. After 3h at room temperature the reaction was quenched with 3mL of water and extract thrice with 3mL of CH 2 Cl 2. The combined organic phases were washed with 5mL of a 2 S 2 O 3 aqueous saturated solution, dried on a 2 SO 4 and evaporated to dryness. The crude mixture was purified by column chromatography (silica, eluent: CH 2 Cl 2 ). 1b is obtained as a gray solid (2.1g, 6.5mmol, yield: 9%). 1 H MR (CDCl 3 ) δ: 8.6 (dt, 1H, J = 6.9Hz,.9Hz, H-5), 7.56 (dt, 1H, J = 9.3Hz,.9Hz, H-8), 7.21 (ddd, J = 9.Hz, 6.9Hz, 1.2Hz, H-7), 6.91 (td, 1H, J = 6.9Hz,.9Hz, H-6). 13 C MR (CDCl 3 ) δ: 147.4 (C-8a), 125.3 (C-7), 124.3 (C-5), 117.3 (C-8), 113.7 (C-6), 11.9 (C-2*), 95.9 (C-3*). m.p.: 114-118 C. HRMS (ESI): m/z calculated for C 7 H 4 BrI 2 [M+H] + : 322.86753, found: 322.86793. General procedure for Suzuki coupling at C-2 position or C-3 position. 1b (646mg, 2mmol, 1eq) or 2b-d (n mmol, 1 eq for C-3 functionalization), Pd(PPh 3 ) 4 (116mg,.1mmol, 5%), a 2 CO 3 (424mg, 4mmol, 2eq) and boronic acid (2.2mmol, 1.1eq) were introduced into a microwave tube. The tube was sealed with a rubber septum and then evacuated and refilled with argon thrice. 1,4-Dioxane (8mL) and water (4mL) were then added. The reaction mixture was heated under microwave iradiation at 12 C for 1h. After cooling, the reaction mixture was partitioned between EtOAc (1mL) and water (1mL). The aqueous phase was extracted twice with EtOAc (1mL). Organic phases were combined, dried over MgSO 4 and evaporated to dryness. The crude mixture was purified by column chromatography (silica, eluent: mixture of CH 2 Cl 2 and EtOAc). 3-bromo-2-(thiophen-3-yl)imidazo[1,2-a]pyridine (2c) 1 Gao, Y.; Yin, M.; Wu, W.; Huang, H.; Jiang, H. Adv. Synth. Catal. 213, 355, 2263-2273. 2 Zhou, X.; Yan, H.; Ma, C.; He, Y.; Li, Y.; Cao, J.; Yan, R.; Huang, G. J. Org. Chem. 216, 81, 25-31. 3 Hiebel, M.-A.; Fall, Y.; Scherrmann, M.-C.; Berteina-Raboin, S. Eur. J. Org. Chem. 214, 4646-465. 4 Marhadour, S.; Marchand, P.; Pagniez, F.; Bazin, M.-A.; Picot, C.; Lozach, O.; Ruchaud, S.; Antoine, M.; Meijer, L.; Rachidi,.; Le Pape, P. Eur. J. Med. Chem. 212, 58, 543-556. 5 Enguehard, C.; Renou, J.-L.; Collot, V.; Hervet, M.; Rault, S.; Gueiffier, A. J. Org. Chem. 2, 65, 6572-6575. 6 Meng, X.; Yu, C.; Chen, G.; Zhao, P. Catal. Sci. Technol. 215, 5, 372-379. 2

Eluent: CH 2 Cl 2 /EtOAc 98/2 97/3. Pale yellow solid, yield: 8%. 1 H MR (CDCl 3 ) δ: 8.4 (m, 2H, H-5, thienyl-2), 7.86 (dd, 1H, J = 4.8Hz, 1.2Hz, thienyl-4), 7.56 (dt, 1H, J = 9.Hz,.9Hz, H-8), 7.39 (dd, 1H, J = 4.8Hz, 3.Hz, thienyl-5), 7.18 (ddd, 1H, J = 9.Hz, 6.6Hz, 1.2Hz, H-7), 6.84 (td, 1H, J = 6.9Hz,.9Hz, H-6). 13 C MR (CDCl 3 ) δ: 145.2 (C-8-a), 139.1 (C-2), 133.9 (thienyl-3), 127. (thienyl-4), 125.8 (thienyl-5), 125.6 (C-7), 124. (C-5), 123.8 (thienyl-2), 117.4 (C-8), 113.4 (C-6), 91.5 (C-3). m.p.: 13-134 C. HRMS (ESI): m/z calculated for C 11 H 7 Br 2 S [M+H] + : 278.95861, found: 278.95892. 3-bromo-2-methylimidazo[1,2-a]pyridine (2d) Eluent: CH 2 Cl 2 /EtOAc 9/1 8/2. Yellow solid, yield: 42%. 1 H MR (CDCl 3 ) δ: 7.99 (dt, 1H, J = 6.9Hz,.9Hz, H-5), 7.48 (dt, 1H, J = 9.Hz,.9Hz, H-8), 7.15 (ddd, 1H, J = 9.Hz, 6.9Hz, 1.2Hz, H-7), 6.84 (td, 1H, J = 6.9Hz,.9Hz, H-6), 2.43 (s, 3H, CH 3 ). 13 C MR (CDCl 3 ) δ: 145.2 (C-8a), 142. (C-2), 124.4 (C-7), 123.7 (C-5), 117. (C-8), 112.6 (C-6), 93. (C-3), 13.7 (CH 3 ). m.p.: 45-49 C. HRMS (ESI): m/z calculated for C 8 H 7 Br 2 [M+H] + : 21.98654, found: 21.98671. 3-(furan-2-yl)-2-phenylimidazo[1,2-a]pyridine (3c) Eluent: CH 2 Cl 2 /EtOAc 95/5. Brown solid, yield: 67%. 1 H MR (CDCl 3 ) δ: 8.19 (dt, 1H, J = 6.9Hz,.9Hz, H-5), 7.77-7.74 (m, 2H, Ph-2,6), 7.66 (dt, 1H, J = 9.Hz,.9Hz, H-8), 7.63 (t, 1H, J = 1.2Hz, furyl- 5), 7.4-7.31 (m, 3H, Ph-3,4,5), 7.22 (ddd, 1H, J = 9.Hz, 6.9Hz, 1.2Hz, H-7), 6.8 (td, 1H, J = 6.9Hz, 1.2Hz, H-6), 6.56 (m, 2H, furyl-3,4). 13 C MR (CDCl 3 ) δ: 145.5 (C-8a), 145.3 (furyl-2), 143.6 (C-2), 143.4 (furyl- 5), 134. (Ph-1), 128.5 (Ph-3,5*), 128.2 (Ph-2,6*), 128.1 (Ph-4), 125.5 (C-7), 124.8 (C-5), 117.6 (C-8), 112.8 (C-6), 111.8 (furyl-3*), 111.6 (furyl-4*). m.p.: 111-115 C. HRMS (ESI): m/z calculated for C 17 H 12 2 O [M+H] + : 261.1224, found: 261.1229. 3-phenyl-2-(thiophen-3-yl)imidazo[1,2-a]pyridine (3e) Eluent: CH 2 Cl 2 /EtOAc 1/ 93/7. white solid, yield: 88%. 1 H MR (CDCl 3 ) δ: 7.91 (dt, 1H J = 6.9Hz, 1.2Hz, H-5), 7.78 (d, 1H, J = 9.3Hz, H-8), 7.65 (dd, 1H, J = 3.Hz, 1.5Hz, thienyl-2), 7.61-7.48 (m, 5H, Ph-2,3,4,5,6), 7.31-7.21 (m, 3H, H-7, thienyl-4,5), 6.8 (td, 1H, J = 6.9Hz, 1.2Hz, H-6). 13 C MR (CDCl 3 ) δ: 143.9 (C-8a), 137.5 (C-2), 134.2 (thienyl-3), 131.1 (Ph-3,5*), 129.8 (Ph-2,6*), 129.7 (Ph-4), 129. (Ph-1), 127. (thienyl-2), 126. (C-7), 125.6 (thienyl-4*), 123.62 (C-5*), 123.59 (thienyl-5*), 12.6 (C-3), 116.9 (C-8), 113.2 (C-6). m.p.: 148-152 C. HRMS (ESI): m/z calculated for C 17 H 12 2 S [M+H] + : 277.794, found: 277.7945. 2-phenyl-3-(pyridin-4-yl)imidazo[1,2-a]pyridine (3f) 4 1b (2mg,.619mmol, 1eq), Pd(PPh 3 ) 4 (36mg,.31mmol, 5%), a 2 CO 3 (131mg, 1.24mmol, 2eq) and phenylboronic acid (83mg,.681mmol, 1.1eq) were introduced into a microwave tube. The tube was sealed with a rubber septum and then evacuated and refilled with argon thrice. 1,4-Dioxane (2.8mL) and water (1.4mL) were then added. The reaction mixture was heated under microwave irradiation at 12 C for 1h. After cooling, 4-pyridylboronic acid (98mg,.681mmol, 1.1eq) was added and the reaction was heated again under microwave irradiation at 12 C for 1h. After cooling, the reaction mixture was partitioned between CH 2 Cl 2 (1mL) and water (1mL). The aqueous phase was extracted twice with CH 2 Cl 2 (1mL). Organic phases were combined, dried over MgSO 4 and evaporated to dryness. The crude mixture was purified by column chromatography (silica, eluent: CH 2 Cl 2 /EtOAc 1/ 93/7) to afford 3a as a white solid (16mg), yield: 73%. General procedure for Sonogashira coupling at C-2 position. 1b (161mg,.5mmol, 1eq), PdCl 2 (PPh 3 ) 2 (35mg,.5mmol, 1%) and CuI (1mg,.5mmol, 1%) were introduced into a screw-cap test tube. The tube was sealed with a rubber septum and then evacuated and refilled with argon thrice. DMF (2mL), Et 3 (278µL, 2mmol, 4eq) and alkyne (.55mmol, 1.1eq) were then added. The reaction mixture was stirred for 3 minutes at room temperature. The reaction mixture was partitioned between CH 2 Cl 2 (1mL) and brine (1mL). The aqueous phase was extracted twice with CH 2 Cl 2 (1mL). Organic phases were combined, dried over MgSO 4 and evaporated to dryness. The crude mixture was purified by column chromatography (silica, eluent: mixture of petroleum ether and diethylether). 3

3-bromo-2-(phenylethynyl)imidazo[1,2-a]pyridine (4a) Eluent: PE/Et 2 O 5/5. Orange solid, yield: 95%. 1 H MR (CDCl 3 ) δ: 8.8 (dt, 1H, J = 6.9Hz,.9Hz, H-5), 7.64-7.61 (m, 3H, 2CH Ph, H-8), 7.38-7.36 (m, 3H, 3CH Ph), 7.31 (ddd, 1H, J = 9.Hz, 6.6Hz, 1.2Hz, H-7), 6.98 (td, 1H, J = 6.9Hz, 1.2Hz, H-6). 13 C MR (CDCl 3 ) δ: 145.1 (C-8a), 132. (2CH Ph), 129. (CH Ph), 128.5 (2CH Ph), 128.4 (C-2), 126.2 (C-7), 124.1 (C-5), 122.5 (Cq Ph), 117.7 (C-8), 114.1 (C-6), 99.4 (C-3), 94.6 (C C-Ph), 81. (C C-Ph). m.p.: 117-121 C. HRMS (ESI): m/z calculated for C 15 H 9 Br 2 [M+H] + : 297.219, found: 297.257. 3-bromo-2-(cyclopropylethynyl)imidazo[1,2-a]pyridine (4b) Eluent: PE/Et 2 O 5/5. Yellow solid, yield: 98%. 1 H MR (CDCl 3 ) δ: 7.96 (dt, 1H, J = 6.9Hz,.9Hz, H-5), 7.47 (dt, 1H, J = 9.3Hz,.9Hz, H-8), 7.19 (ddd, 1H, J = 9.Hz, 6.9Hz, 1.2Hz, H-7), 6.87 (td, 1H, J = 6.9Hz,.9Hz, H-6), 1.5 (quint, 1H, CH c-pr),.88 (m, 4H, 2CH 2 c-pr). 13 C MR (CDCl 3 ) δ: 144.9 (C-8a), 129.1 (C-2), 125.5 (C-7), 123.8 (C-5), 117.5 (C-8), 113.6 (C-6), 98.9 (C C-c-Pr), 98.4 (C-3), 67.6 (C C-c-Pr), 9. (2CH 2 c-pr),.4 (CH c-pr). m.p.: 79-83 C. HRMS (ESI): m/z calculated for C 12 H 9 Br 2 [M+H] + : 261.219, found: 261.244. General procedure for Sonogashira coupling at C-3 position. 4a-b (.5mmol, 1eq), PdCl 2 (PPh 3 ) 2 (35mg,.5mmol, 1%) and CuI (1mg,.5mmol, 1%) were introduced into a screw-cap test tube. The tube was sealed with a rubber septum and then evacuated and refilled with argon thrice. DMF (2mL), Et 3 (278µL, 2mmol, 4eq) and alkyne (.55mmol, 1.1eq) were then added. The reaction mixture was stirred for 1h3 at 8 C. After cooling, the reaction mixture was partitioned between CH 2 Cl 2 (1mL) and brine (1mL). The aqueous phase was extracted twice with CH 2 Cl 2 (1mL). Organic phases were combined, dried over MgSO 4 and evaporated to dryness. The crude mixture was purified by column chromatography (silica, eluent: mixture of petroleum ether and diethylether). 2-(phenylethynyl)-3-(p-tolylethynyl)imidazo[1,2-a]pyridine (5a) Eluent: PE/Et 2 O 5/5. Orange solid, yield: 97%. 1 H MR (CDCl 3 ) δ: 8.29 (d, 1H, J = 6.6Hz, H-5), 7.65-7.62 (m, 3H, Ph-2,6, H-8), 7.51 (d, 2H, J = 8.1Hz, tolyl-2,6), 7.39- (m, 3H, Ph-3,4,5), 7.32 (ddd, 1H, J = 9.Hz, 6.9Hz, 1.2Hz, H-7), 7.21 (d, 2H, J = 7.8Hz, tolyl-3,5), 6.97 (td, 1H, J = 6.6Hz,.9Hz, H-6), 2.4 (s, 3H, CH 3 tolyl). 13 C MR (CDCl 3 ) δ: 144.7 (C-8a), 139.5 (tolyl-4), 132. (Ph-2,6), 131.9 (C-2), 131.5 (tolyl-2,6), 129.4 (tolyl-3,5), 128.9 (Ph-4), 128.5 (Ph-3,5), 127.1 (C-7), 125.3 (C-5), 122.7 (Ph-1), 119.3 (tolyl-1), 117.6 (C-8), 113.8 (C-6), 112.2 (C-3), 12.3 (C C-tolyl), 94.7 (C C-Ph), 82.3 (C C-Ph), 75.2 (C C-tolyl), 21.7 (CH 3 tolyl). m.p.: 113-117 C. HRMS (ESI): m/z calculated for C 24 H1 7 2 [M+H] + : 333.13917, found: 333.13888. 3-(cyclopropylethynyl)-2-(phenylethynyl)imidazo[1,2-a]pyridine (5b) Eluent: PE/Et 2 O 5/5 4/6. Brown solid, yield: 82%. 1 H MR (CDCl 3 ) δ: 8.16 (dt, 1H, J = 6.9Hz,.9Hz, H-5), 7.63-7.59 (m, 2H, Ph-2,6), 7.54 (dt, 1H, J = 9.Hz,.9Hz, H-8), 7.38-7.33 (m, 3H, Ph- 3,4,5), 7.24 (ddd, 1H, J = 9.Hz, 6.6Hz, 1.2Hz, H-7), 6.88 (td, 1H, J = 6.6Hz,.9Hz, H-6), 1.7-1.61 (m, 1H, CH c-pr), 1.4-.91 (m, 4H, 2CH 2 c-pr). 13 C MR (CDCl 3 ) δ: 144.5 (C-8a), 132. (Ph-2,6), 131.9 (C-2), 128.7 (Ph-4), 128.4 (Ph-3,5), 126.3 (C-7), 125.1 (C-5), 123. (Ph-1), 117.6 (C-8), 113.3 (C-6), 112.5 (C-3), 16.8 (C C-c-Pr), 93.7 (C C-Ph), 82.8 (C C-Ph), 62.4 (C C-c-Pr), 9.6 (2CH 2 c-pr),.8 (CH c-pr). m.p.: 15-19 C. HRMS (ESI): m/z calculated for C 2 H 14 2 [M+H] + : 283.12298, found: 283.12315. 3-(3-methoxyprop-1-yn-1-yl)-2-(phenylethynyl)imidazo[1,2-a]pyridine (5c) Eluent: PE/Et 2 O 4/6. Brown oil, yield: 42%. 1 H MR (CDCl 3 ) δ: 8.22 (dt, 1H, J = 6.9Hz,.9Hz, H-5), 7.62-7.57 (m, 3H, Ph-2,6, H-8), 7.38-7.34 (m, 3H, Ph-3,4,5), 7.3 (ddd, 1H, J = 9.Hz, 6.9Hz, 1.2Hz, H-7), 6.94 (td, 1H, J = 6.9Hz,.9Hz, H-6), 4.53 (s, 2H, CH 2 OCH 3 ), 3.52 (s, 3H, CH 2 OCH 3 ). 13 C MR (CDCl 3 ) δ: 145.1 (C-8a), 133.2 (C-2), 132. (Ph-2,6), 128.9 (Ph-4), 128.5 (Ph-3,5), 126.9 (C-7), 125.2 (C- 5), 122.7 (Ph-1), 117.8 (C-8), 113.7 (C-6), 111.2 (C-3), 98.2 (C C-CH 2 OCH 3 ), 94.1 (C C-Ph), 82.3 (C C- Ph), 73.5 (C C-CH 2 OCH 3 ), 6.8 (CH 2 OCH 3 ), 57.9 (CH 2 OCH 3 ). HRMS (ESI): m/z calculated for C 19 H 14 2 O [M+H] + : 287.11789, found: 287.11822. 4

2-(cyclopropylethynyl)-3-(phenylethynyl)imidazo[1,2-a]pyridine (5d) Eluent: PE/Et 2 O 5/5. Brown oil, yield: 54%. 1 H MR (CDCl 3 ) δ: 8.23 (dt, 1H, J = 6.9Hz,.9Hz, H-5), 7.6-7.54 (m, 3H, Ph-2,6, H-8), 7.41-7.37 (m, 3H, Ph-3,4,5), 7.27 (ddd, 1H, J = 8.7Hz, 6.6Hz, 1.2Hz, H-7), 6.93 (td, 1H, J = 6.9Hz, 1.2Hz, H-6), 1.6-1.51 (m, 1H, CH c-pr),.93-.9 (m, 4H, 2CH 2 c-pr). 13 C MR (CDCl 3 ) δ: 144.6 (C-8a), 132.9 (C-2), 131.5 (Ph-2,6), 128.9 (Ph-4), 128.6 (Ph-3,5), 126.8 (C-7), 125.1 (C-5), 122.5 (Ph-1), 117.5 (C-8), 113.6 (C-6), 113.3 (C-3), 11.5 (C C-Ph), 99.5 (C C-c-Pr), 76.1 (C C- Ph), 68.5 (C C-c-Pr), 9.1 (2CH 2 c-pr),.6 (CH c-pr). HRMS (ESI): m/z calculated for C 2 H 14 2 [M+H] + : 283.12298, found: 283.12319. 3-((4-methoxyphenyl)ethynyl)-2-(phenylethynyl)imidazo[1,2-a]pyridine (5e) 1b (2mg,.619mmol, 1eq), PdCl 2 (PPh 3 ) 2 (43mg,.62mmol, 1%) and CuI (12mg,.62mmol, 1%) were introduced into a screw-cap test tube. The tube was sealed with a rubber septum and then evacuated and refilled with argon thrice. DMF (2.5mL), Et 3 (344µL, 2.48mmol, 4eq) and phenylacetylene (75µL,.68mmol, 1.1eq) were then added. The reaction mixture was stirred for 3 minutes at room temperature. 4-methoxyphenylacetylene (12µL,.929mmol, 1.5eq) was added, and the reaction heated at 8 C for 1h3. After cooling, the reaction mixture was partitioned between CH 2 Cl 2 (12mL) and brine (12mL). The aqueous phase was extracted twice with CH 2 Cl 2 (12mL). Organic phases were combined, dried over MgSO 4 and evaporate to dryness. The crude mixture was purified by column chromatography (silica, eluent: PE/Et 2 O 4/6 2/8) to afford 5e as a dark yellow solid (14mg), yield: 65%. 1 H MR (CDCl 3 ) δ: 8.25 (dt, 1H, J = 6.6Hz,.9Hz, H-5), 7.65-7.59 (m, 3H, Ph-2,6, H-8), 7.54 (d, 2H, J = 8.7Hz, 4-MeOPh- 2,6), 7.37-7.34 (m, 3H, Ph-3,4,5), 7.29 (ddd, 1H, J = 9.Hz, 6.9Hz, 1.5Hz, H-7), 6.96-6.89 (m, 3H, 4-MeOPh- 3,5, H-6), 3.83 (s, 3H, OCH 3 ). 13 C MR (CDCl 3 ) δ: 16.3 (4-MeOPh-4), 144.7 (C-8a), 133.4 (C-2*), 133.2 (4-MeOPh-2,6), 132. (Ph-2,6), 131.7 (4-MeOPh-1*), 128.8 (Ph-4), 128.4 (Ph-3,5), 126.9 (C-7), 125.2 (C- 5), 122.7 (Ph-1), 117.6 (C-8), 114.3 (4-MeOPh-3,5), 113.7 (C-6), 112.3 (C-3), 12.1 (C C-4-MeOPh), 94.5 (C C-Ph), 82.4 (C C-Ph*), 74.5 (C C-4-MeOPh*), 55.4 (OCH 3 ). m.p.: 54-58 C. HRMS (ESI): m/z calculated for C 24 H 16 2 O [M+H] + : 349.13354, found: 349.13389. 2-methyl-3-(phenylethynyl)imidazo[1,2-a]pyridine (6b) Eluent: PE/Et 2 O 5/5 2/8. Orange oil, yield: 67%. 1 H MR (CDCl 3 ) δ: 8.24 (dt, 1H, J = 6.9Hz,.9Hz, H-5), 7.57-7.53 (m, 3H, Ph-2,6, H-8), 7.4-7.33 (m, 3H, Ph-3,4,5), 7.21 (ddd, 1H, J = 9.Hz, 6.9Hz, 1.2Hz, H-7), 6.87 (td, 1H, J = 6.9Hz, 1.2Hz, H-6), 2.58 (s, 3H, CH 3 ). 13 C MR (CDCl 3 ) δ: 148.5 (C-2), 144.9 (C-8a), 131.3 (Ph-2,6), 128.6 (Ph-3,4,5), 125.7 (C-7), 125.1 (C-5), 122.9 (Ph-1), 116.9 (C-8), 112.8 (C-6), 16.4 (C-3), 1.7 (C C-Ph), 76.9 (C C-Ph), 14.4 (CH 3 ). HRMS (ESI): m/z calculated for C 16 H 12 2 [M+H] + : 233.1732, found: 233.1744. 3-methyl-2-(phenylethynyl)imidazo[1,2-a]pyridine (6c) Eluent: CH 2 Cl 2 /MeOH 99/1. Brown solid, yield: 7%. 1 H MR (CDCl 3 ) δ: 7.82 (dt, 1H, J = 6.9Hz,.9Hz, H-5), 7.6-7.53 (m, 3H, Ph-2,6, H-8), 7.37-7.33 (m, 3H, Ph-3,4,5), 7.18 (ddd, 1H, J = 9.3Hz, 6.9Hz, 1.2Hz, H-7), 6.85 (td, 1H, J = 6.6Hz,.9Hz, H-6), 2.59 (s, 3H, CH 3 ). 13 C MR (CDCl 3 ) δ: 144.5 (C-8a), 131.7 (Ph-2,6), 128.4 (Ph-3,4,5), 126.5 (C-2), 124.4 (C-7), 123.8 (C-3*), 123.2 (Ph-1*), 122.9 (C-5), 117.7 (C-8), 112.8 (C-6), 92.7 (C C-Ph), 83.1 (C C-Ph), 9.2 (CH 3 ). m.p.: 119-123 C. HRMS (ESI): m/z calculated for C 16 H 12 2 [M+H] + : 233.1732, found: 233.175. 2-(phenylethynyl)-3-(pyridin-4-yl)imidazo[1,2-a]pyridine (6d) Eluent: CH 2 Cl 2 /MeOH 99/1. Off-white solid, yield: 89%. 1 H MR (CDCl 3 ) δ: 8.81 (bd, 1H, J = 4.5Hz, Pyridyl-2,6), 8.37 (d, 1H, J = 7.2Hz, H-5), 7.76 (d, 1H, J = 5.7Hz, Pyridyl-3,5), 7.67 (d, 1H, J = 9.Hz, H-8), 7.54-7.48 (m, 2H, Ph-2,6), 7.37-7.3 (m, 4H, Ph-3,4,5, H-7), 6.93 (td, 1H, J = 6.9Hz,.9Hz, H- 6). 13 C MR (CDCl 3 ) δ: 15.1 (Pyridyl-2,6), 146.2 (C-8a), 136.9 (Pyridyl-4), 131.9 (Ph-2,6), 129. (Ph-4), 128.9 (C-2), 128.6 (Ph-3,5), 126.8 (C-7), 124.6 (Ph-1), 123.4 (C-5), 122.4 (Pyridyl-3,5), 118.5 (C-8), 114.2 (C-6), 93.4 (C C-Ph), 82.7 (C C-Ph), (C-3 is missing). m.p.: 87-91 C. HRMS (ESI): m/z calculated for C 2 H 13 3 [M+H] + : 296.11822, found: 296.11851. 5

8.5 8. 2,3-diiodoimidazo[1,2-a]pyridine (1a) 1 H MR (CDCl 3 ) 7.5 7. 6.5 1. 1.5 1.8 1.6 8.8 8.5 7.56 7.53 7.26 Chlor 7.21 7.2 6.92 6.92 6.89 6.89 6.87 6.87 6. 5.5 5. I I 4.5 4. 3.5 3. 2.5 2. 1.5 1..5 2,3-diiodoimidazo[1,2-a]pyridine (1a) 13 C MR (CDCl 3 ). 3E+9 3E+9 2E+9 2E+9 2E+9 2E+9 2E+9 1E+9 1E+9 1E+9 8E+8 6E+8-6

15 149.44 14 13 126.96 125.71 12 117.16 113.9 11 14.6 1 9 8 77.16 Chloro 73.1 7 6 I 5 I 4 3 2 1 3-bromo-2-iodoimidazo[1,2-a]pyridine (1b) 1 H MR (CDCl 3 ) 7E+8 6E+8 6E+8 6E+8 5E+8 3E+8 1E+8 5E+7-5E+7 7

8.5 8. 7.5 7. 6.5 1. 1. 1.14 1.16 8.7 8.7 8.7 8.5 8.5 8.4 7.58 7.55 7.54 7.26 Chloro 7.22 6.94 6.93 6.91 6.91 6.89 6.89 6. 5.5 5. Br I 4.5 4. 3.5 3. 2.5 2. 1.5 1..5. 3-bromo-2-iodoimidazo[1,2-a]pyridine (1b) 13 C MR (CDCl 3 ) 2E+9 1E+9 1E+9 1E+9 1E+9 1E+9 9E+8 8E+8 7E+8 6E+8 5E+8 3E+8 1E+8-1E+8 8

147.38 14 13 125.31 124.29 12 117.28 113.75 11 1 11.88 95.87 9 8 7 77.16 Chloro 6 Br 5 I 4 3 2 1 2-iodo-3-phenylimidazo[1,2-a]pyridine (2a) 1 H MR (CDCl 3 ) 9E+8 8E+8 7E+8 6E+8 5E+8 3E+8 1E+8-1E+8 9

8. 7.5 7. 6.5 1.2 1.4 4.85 1.3 1. 8.8 8.5 7.63 7.6 7.56 7.54 7.5 7.26 Chloro 7.21 7.19 7.19 6.78 6.78 6.76 6.75 6.73 6.73 6. 5.5 5. I 4.5 4. 3.5 3. 2.5 2. 1.5 1. 2-iodo-3-phenylimidazo[1,2-a]pyridine (2a) 13 C MR (CDCl 3 ).5 6E+8 6E+8 6E+8 5E+8 3E+8 1E+8 5E+7-5E+7 1

15 146.96 14 13 12 13.19 129.35 128.39 125.13 123.3 117.26 112.98 11 1 93.66 9 8 7 77.16 Chloro 6 5 4 I 3 2 1 3-bromo-2-phenylimidazo[1,2-a]pyridine (2b) 1 H MR (CDCl 3 ) 6E+8 5E+8 3E+8 1E+8-1E+8 - -3E+8 11

12..5 1. 1.5 2. 2.5 3. 3.5 4. 4.5 5. 5.5 6. 6.5 7. 7.5 8. 8.5-1E+8 1E+8 3E+8 5E+8 6E+8 7E+8 8E+8 9E+8 1E+9 1E+9 1E+9 1E+9 1E+9 2E+9 2E+9 1. 1.23.94 1.96 1.3 2.88 6.9 6.9 6.92 6.92 6.94 6.95 7.26 Chloro 7.39 7.46 7.49 7.63 7.66 8.11 8.12 8.14 8.15 8.15 8.17 Br 6.8 6.9 7. 7.1 7.2 7.3 7.4 7.5 7.6 7.7 7.8 7.9 8. 8.1 8.2 8.3 1E+8 3E+8 5E+8 1. 1.23.94 1.96 1.3 2.88 6.9 6.9 6.92 6.92 6.94 6.95 7.23 7.23 7.25 7.26 Chloroform-d 7.28 7.28 7.36 7.39 7.41 7.42 7.46 7.49 7.51 7.63 7.66 8.11 8.12 8.14 8.15 8.15 8.17 3-bromo-2-phenylimidazo[1,2-a]pyridine (2b) 13 C MR (CDCl 3 )

14 145.32 142.49 13 12 132.8 128.44 128.27 127.83 125.8 123.86 117.47 113. 11 1 9 91.68 8 7 77.16 Chloro 6 Br 5 4 3 2 1 3-bromo-2-(thiophen-3-yl)imidazo[1,2-a]pyridine (2c) 1 H MR (CDCl 3 ) 6E+8 5E+8 3E+8 1E+8 5E+7-5E+7 13

8.5 8. 7.5 7. 1.69.86 1..95 1.33 1.6 8.8 8.7 7.9 7.89 7.88 7.88 7.62 7.43 7.42 7.41 7.4 7.26 7.26 Chloro 6.95 6.93 6.9 6.5 6. 8.3 5.5 5. 8.2 8.1 8. 8.15 8.12 8.8 8.7 4.5 4. 3.5 3. 2.5 2. 7.9 7.8 7.7 7.6 7.5 7.4 7.3 7.2 7.1 7.9 7.89 7.88 7.88 7.66 7.62 7.43 7.42 7.41 7.4 7.29 7.29 7.26 7.26 Chloroform-d 7.24 7.23 Br S 1.5 7. 6.9 6.95 6.93 6.9 6.8 1. 6.7 6E+8 5E+8 3E+8 1E+8.5. 3-bromo-2-(thiophen-3-yl)imidazo[1,2-a]pyridine (2c) 13 C MR (CDCl 3 ) -.5 9E+8 8E+8 7E+8 6E+8 5E+8 3E+8 1E+8 14

145.16 14 139.9 133.89 13 12 127.5 125.81 125.56 123.99 123.78 117.38 113.36 11 1 9 91.5 8 77.16 Chloro 7 6 Br 5 S 4 3 2 1 3-bromo-2-methylimidazo[1,2-a]pyridine (2d) 1 H MR (CDCl 3 ) -1 1E+9 1E+9 9E+8 8E+8 7E+8 6E+8 5E+8 3E+8 1E+8-1E+8 15

8..92 8. 7.98 7.5 7. 6.5.91 1.1 1. 8.1 7.9 8. 7.98 7.49 7.46 7.26 Chloro 7.18 7.16 7.16 7.15 6.86 6.86 6.84 6.83 6.82 6.81 7.7 6. 5.5 5. 4.5 4. 7.5 7.3 7.1 6.9 6.7 7.49 7.46 7.26 Chloroform-d 7.18 7.18 7.16 7.16 7.15 7.15 7.13 7.13 6.86 6.86 6.84 6.83 6.82 6.81 3.5 9E+7 8E+7 7E+7 6E+7 5E+7 4E+7 3E+7 2E+7 1E+7 3. 2.5 3.29 2.43 2. 1.5 Br 1. CH 3.5. 3-bromo-2-methylimidazo[1,2-a]pyridine (2d) 13 C MR (CDCl 3 ) 3E+8 1E+8 5E+7 16

145.22 14 141.99 13 124.38 123.67 12 117.2 112.63 11 1 93. 9 8 77.16 Chloro 7 6 5 Br CH 3 4 3 2 13.68 1 2-phenyl-3-(p-tolyl)imidazo[1,2-a]pyridine (3a) 1 H MR (CDCl 3 ) 8E+8 7E+8 6E+8 6E+8 6E+8 5E+8 3E+8 1E+8 5E+7-5E+7 17

8. 7.5.99 2.77 7.72 7.71 7.7 7.69 7.69 7.67 7. 6.5 6. 6.98 1.1 1. 8. 7.8 7.6 7.95 7.93 7.72 7.71 7.7 7.69 7.69 7.67 7.33 7.29 7.27 7.26 Chloro 6.73 6.73 6.71 6.71 6.69 6.68 5.5 5. 4.5 4. 3.5 7.4 7.2 7. 6.8 6.6 7.33 7.29 7.27 7.26 Chloroform-d 7.24 7.21 7.21 7.19 7.18 7.18 7.17 7.16 7.15 6.73 6.73 6.71 6.71 6.69 6.68 3E+8 1E+8 3. 2.5 2.46 2. 1.5 1. CH 3.5. 2-phenyl-3-(p-tolyl)imidazo[1,2-a]pyridine (3a) 13 C MR (CDCl 3 ) 6E+8 6E+8 6E+8 5E+8 3E+8 1E+8 5E+7-5E+7 18

145 14 144.74 142.16 138.93 135 13 125 12 115 11 134.28 13.63 13.35 128.31 128.1 127.48 126.78 124.68 123.4 117.49 112.26 15 1 95 9 85 8 77.16 Chloro 75 7 65 6 55 5 CH 3 45 4 35 3 25 2 3-(4-methoxyphenyl)-2-phenylimidazo[1,2-a]pyridine (3b) 1 H MR (CDCl 3 ) 15 21.52 1E+9 9E+8 8E+8 7E+8 6E+8 5E+8 3E+8 1E+8-1E+8 19

9.5 9. 8.5 8. 7.5 7. 6.5 6. 5.5.95 2.85 1.95 3. 1.14 1.97 1. 8. 7.8 7.6 7.4 7.2 7. 6.8 6.6 7.93 7.92 7.92 7.9 7.9 7.9 7.72 7.71 7.69 7.69 7.66 7.38 7.29 7.27 7.26 Chloroform-d 7.24 7.21 7.21 7.19 7.18 7.18 7.18 7.7 7.4 6.74 6.74 6.72 6.72 6.7 6.69 7.92 7.9 7.9 7.9 7.72 7.71 7.69 7.69 7.66 7.38 7.29 7.27 7.26 Chloro 7.24 7.21 7.19 7.18 7.18 7.7 7.4 6.74 6.74 6.72 6.72 6.7 6.69 5. 3E+8 1E+8 4.5 4. 3.9 3.89 3.5 3. 2.5 2. H 3 C 1.5 O 1..5. -.5 3-(4-methoxyphenyl)-2-phenylimidazo[1,2-a]pyridine (3b) 13 C MR (CDCl 3 ) -1. 3E+8 1E+8 5E+7 2

6 16.9 15 14 13 12 11 144.74 142.24 134.43 132.19 128.35 128.4 127.46 124.58 123.41 121.93 12.98 117.57 115.13 112.23 1 9 8 77.16 Chloro 7 6 55.46 5 4 H 3 C 3 O 2 1 3-(furan-2-yl)-2-phenylimidazo[1,2-a]pyridine (3c) 1 H MR (CDCl 3 ) 6E+8 6E+8 5E+8 3E+8 1E+8 5E+7-5E+7 21

22 -.5..5 1. 1.5 2. 2.5 3. 3.5 4. 4.5 5. 5.5 6. 6.5 7. 7.5 8. 8.5 5E+7 1E+8 3E+8 1.81 1.8 1.7 3.19.82 1.1 2.1 1. 6.56 6.57 6.77 6.78 6.8 6.8 6.82 6.82 7.37 7.63 7.65 7.74 7.74 7.76 7.77 8.18 8.18 8.18 8.2 8.2 8.21 O 6.5 6.7 6.9 7.1 7.3 7.5 7.7 7.9 8.1 8.3 1E+8 3E+8 5E+8 6.56 6.57 6.77 6.78 6.8 6.8 6.82 6.82 7.22 7.22 7.23 7.23 7.25 7.25 7.26 Chloroform-d 7.31 7.33 7.37 7.39 7.62 7.63 7.63 7.65 7.68 7.68 7.74 7.74 7.76 7.77 8.18 8.18 8.18 8.2 8.2 8.21 3-(furan-2-yl)-2-phenylimidazo[1,2-a]pyridine (3c) 13 C MR (CDCl 3 )

14 145.48 145.26 143.6 143.44 134.3 13 12 11 128.46 128.24 128.15 125.49 124.76 117.63 112.79 111.84 111.59 1 9 8 7 77.16 Chloro 6 5 O 4 3 2 1 3-methyl-2-phenylimidazo[1,2-a]pyridine (3d) 1 H MR (CDCl 3 ) 6E+8 5E+8 3E+8 1E+8 5E+7-5E+7 23

.5 8. 7.5 7. 6.5 6. 5.5 5. 1.5 2.9 1.12 2.6.97 1.5 1. 8. 7.9 7.8 7.7 7.6 7.5 7.4 7.3 7.2 7.1 7. 7.9 7.88 7.82 7.81 7.79 7.66 7.63 7.49 7.47 7.44 7.38 7.37 7.33 7.33 7.32 7.26 Chloroform-d 7.2 7.2 7.18 7.17 7.17 7.17 7.15 7.14 7.88 7.82 7.81 7.79 7.66 7.63 7.49 7.47 7.44 7.37 7.26 Chloro 7.18 7.17 6.86 6.86 6.84 6.84 6.82 6.82 4.5 4. 6.9 6.8 6.86 6.86 6.84 6.84 6.82 6.82 CH 3 6.7 3.5 1E+8 1E+8 1E+8 8E+7 6E+7 4E+7 2E+7 3. 2.5 3.19 2.64 2. 1.5 1..5. 3-methyl-2-phenylimidazo[1,2-a]pyridine (3d) 13 C MR (CDCl 3 ) -.5 3E+8 1E+8 5E+7 24

14 144.48 142.57 134.98 13 12 11 128.63 128.49 127.48 123.62 122.96 117.58 116.2 112.15 1 9 8 77.16 Chloro 7 6 CH 3 5 4 3 2 1 3-phenyl-2-(thiophen-3-yl)imidazo[1,2-a]pyridine (3e) 1 H MR (CDCl 3 ) 9.76 6E+8 5E+8 3E+8 1E+8 5E+7-5E+7 25

8. 7.5 7. 6.5.97.93.99 4.77 3.37 1. 7.9 7.75 7.63 7.63 7.56 7.51 7.48 7.48 7.27 7.26 Chloro 7.23 6.82 6.81 6.79 6.79 6.77 6.77 6. 5.5 5. 8. 7.9 7.8 7.92 7.92 7.92 7.9 7.9 7.89 7.78 7.75 4.5 4. 3.5 3. 7.7 7.6 7.5 7.4 7.3 7.2 7.1 7.63 7.63 7.63 7.62 7.56 7.51 7.48 7.48 7.3 7.29 7.27 7.26 Chloroform-d 7.23 7.21 S 7. 2.5 2. 6.9 6.8 6.7 6.82 6.81 6.79 6.79 6.77 6.77 6.6 1.5 6E+8 5E+8 3E+8 1E+8 1..5. 3-phenyl-2-(thiophen-3-yl)imidazo[1,2-a]pyridine (3e) 13 C MR (CDCl 3 ) -.5 5E+8 3E+8 1E+8 5E+7 26

143.95 14 13 12 11 137.46 134.24 131.1 129.85 129.67 129.3 127.2 126.1 125.64 123.59 12.64 116.89 113.18 1 9 8 77.16 Chloro 7 6 5 4 S 3 2 1 2-phenyl-3-(pyridin-4-yl)imidazo[1,2-a]pyridine (3f) 1 H MR (CDCl 3 ) -1 7E+8 6E+8 6E+8 6E+8 5E+8 3E+8 1E+8 5E+7-5E+7 27

5 9. 8.5 8. 7.5 7. 6.5 1.96 1.1 1.2 2.33 6.17 1. 8.79 8.15 8.12 7.63 7.62 7.61 7.6 7.44 7.43 7.34 7.33 7.26 Chloro 6.95 6.92 6.9 6. 9. 5.5 8.79 5. 8.5 4.5 4. 3.5 3. 2.5 2. 1.5 1. 8. 7.5 7. 8.15 8.12 7.88 7.85 7.63 7.62 7.61 7.6 7.44 7.43 7.37 7.36 7.34 7.33 7.26 Chloroform-d 6.95 6.92 6.9.5. 2-phenyl-3-(pyridin-4-yl)imidazo[1,2-a]pyridine (3f) 13 C MR (CDCl 3 ) 5E+7 1E+8 3E+8 -.5 5E+8 3E+8 1E+8 5E+7 28

6 15 15.95 144.97 143.1 14 13 12 137.74 132.13 128.85 128.68 126.99 124.83 123.23 118.32 117.64 114.7 11 1 9 8 77.16 Chloro 7 6 5 4 3 2 1 3-bromo-2-(phenylethynyl)imidazo[1,2-a]pyridine (4a) 1 H MR (CDCl 3 ) -1 7E+8 6E+8 6E+8 6E+8 5E+8 3E+8 1E+8 5E+7-5E+7 29

3 -.5..5 1. 1.5 2. 2.5 3. 3.5 4. 4.5 5. 5.5 6. 6.5 7. 7.5 8. 8.5-1E+8 1E+8 3E+8 5E+8 6E+8 7E+8 8E+8 9E+8 1E+9 1E+9 1E+9 1.6 1.19 3.2 3.17 1. 6.96 6.96 6.98 6.98 7. 7.1 7.37 7.38 7.61 7.64 8.6 8.7 8.7 8.9 8.9 8.9 Br 6.8 6.9 7. 7.1 7.2 7.3 7.4 7.5 7.6 7.7 7.8 7.9 8. 8.1 8.2 1E+8 3E+8 5E+8 6E+8 7E+8 6.96 6.96 6.98 6.98 7. 7.1 7.26 Chloroform-d 7.28 7.3 7.31 7.31 7.31 7.33 7.34 7.37 7.38 7.38 7.61 7.62 7.63 7.64 8.6 8.7 8.7 8.9 8.9 8.9 3-bromo-2-(phenylethynyl)imidazo[1,2-a]pyridine (4a) 13 C MR (CDCl 3 )

145.17 14 13 12 132.1 129.2 128.5 126.23 124.1 122.51 117.72 114.9 11 1 99.44 94.65 9 8 81.3 77.16 Chloro 7 6 5 Br 4 3 2 1 3-bromo-2-(cyclopropylethynyl)imidazo[1,2-a]pyridine (4b) 1 H MR (CDCl 3 ) -1 8E+8 7E+8 6E+8 6E+8 6E+8 5E+8 3E+8 1E+8 5E+7-5E+7 31

8.5 8. 7.5 7. 6.5.93.95 1. 1. 7.98 7.98 7.97 7.96 7.95 7.95 7.49 7.46 7.2 7.2 7.19 6.9 6.9 6.88 6.87 6.85 6.85 6. 5.5 5. Br 4.5 4. 3.5 3. 2.5 2. 1.5.8 1.54 1.52 1.5 1.47 1.45 1. 4.11.89.87.5 3-bromo-2-(cyclopropylethynyl)imidazo[1,2-a]pyridine (4b) 13 C MR (CDCl 3 ). 6E+8 5E+8 3E+8 1E+8 5E+7-5E+7 32

144.9 14 13 12 129.9 125.49 123.83 117.49 113.56 11 1 98.91 98.39 9 8 7 77.16 Chloro 67.57 6 5 Br 4 3 2 1 8.97 2-(phenylethynyl)-3-(p-tolylethynyl)imidazo[1,2-a]pyridine (5a) 1 H MR (CDCl 3 ).4 9E+8 8E+8 7E+8 6E+8 5E+8 3E+8 1E+8 33

8. 7.5 7. 6.5 6. 5.5 5..95 2.85 1.92 3.84 1.9 1. 8.3 8.1 7.9 7.7 7.5 8.3 8.28 7.66 7.64 7.63 7.62 7.53 7.5 8.3 8.28 7.66 7.64 7.63 7.62 7.53 7.5 7.38 7.37 7.36 7.33 7.33 7.32 7.3 7.3 7.26 Chloro 7.22 7.2 7. 6.99 6.97 6.97 6.95 6.95 4.5 4. 3.5 7.3 7.1 6.9 7.37 7.36 7.33 7.26 Chloroform-d 7.22 7.2 7. 6.99 6.97 6.97 6.95 6.95 3. 6E+8 5E+8 3E+8 1E+8 2.5 2.76 2.4 2. 1.5 1. CH 3.5 2-(phenylethynyl)-3-(p-tolylethynyl)imidazo[1,2-a]pyridine (5a) 13 C MR (CDCl 3 ). 6E+8 6E+8 5E+8 3E+8 1E+8 5E+7-5E+7 34

144.73 14 139.46 13 12 11 132.4 131.51 129.44 128.91 128.48 127.1 125.3 122.73 119.32 117.65 113.83 112.24 1 12.34 94.72 9 82.28 8 7 77.16 Chloro 75.25 6 5 CH 3 4 3 2 21.73 1 3-(cyclopropylethynyl)-2-(phenylethynyl)imidazo[1,2-a]pyridine (5b) 1 H MR (CDCl 3 ) 6E+8 6E+8 6E+8 5E+8 3E+8 1E+8 5E+7-5E+7 35

36..5 1. 1.5 2. 2.5 3. 3.5 4. 4.5 5. 5.5 6. 6.5 7. 7.5 8. 8.5-5E+7 5E+7 1E+8 3E+8 5E+8 4.6.81 1. 1.39 2.96 1.8 1.95.91.91.95.98.99 1.2 1.3 1.4 1.61 1.63 1.65 1.65 1.68 1.7 6.86 6.86 6.88 6.89 6.9 6.91 7.26 Chloro 7.34 7.36 7.59 7.6 8.15 8.15 8.16 8.17 8.18 8.18 6.8 7. 7.2 7.4 7.6 7.8 8. 8.2 1E+8 3E+8 5E+8 6.88 6.89 6.9 6.91 7.23 7.24 7.24 7.24 7.26 Chloroform-d 7.27 7.34 7.36 7.52 7.52 7.53 7.55 7.55 7.56 7.59 7.6 7.61 7.63 8.15 8.15 8.16 8.17 8.18 8.18 3-(cyclopropylethynyl)-2-(phenylethynyl)imidazo[1,2-a]pyridine (5b) 13 C MR (CDCl 3 )

144.51 14 13 12 11 131.98 131.93 128.7 128.42 126.35 125.9 122.96 117.65 113.28 112.52 16.84 1 93.66 9 82.76 8 77.16 Chloro 7 62.39 6 5 4 3 2 1 9.62 3-(3-methoxyprop-1-yn-1-yl)-2-(phenylethynyl)imidazo[1,2-a]pyridine (5c) 1 H MR (CDCl 3 ).84 8E+8 8E+8 7E+8 6E+8 6E+8 6E+8 5E+8 3E+8 1E+8 5E+7-5E+7 37

8.5 8.2 8.23 8.21 8. 7.5 7. 6.5 6. 5.5.93 2.92 2.87 1.2 1. 8. 7.8 7.6 7.4 7.2 7. 6.8 7.62 7.6 7.6 7.59 7.57 7.37 7.37 7.36 7.26 Chloroform-d 6.96 6.96 6.94 6.94 6.92 6.91 8.23 8.21 7.6 7.6 7.59 7.37 7.36 7.26 Chloro 6.96 6.96 6.94 6.94 6.92 6.91 1E+8 5E+7 5. 4.5 4. 1.97 4.53 3.5 2.82 3.52 3. 2.5 2. 1.5 O CH 3 1..5. 3-(3-methoxyprop-1-yn-1-yl)-2-(phenylethynyl)imidazo[1,2-a]pyridine (5c) 13 C MR (CDCl 3 ) -.5 7E+8 6E+8 6E+8 6E+8 5E+8 3E+8 1E+8 5E+7-5E+7 38

145.6 14 13 12 11 133.2 132.3 128.91 128.46 126.9 125.22 122.69 117.82 113.71 111.16 1 98.18 94.14 9 82.31 8 7 77.16 Chloro 73.54 6 6.76 57.87 5 4 3 O 2 CH 3 1 2-(cyclopropylethynyl)-3-(phenylethynyl)imidazo[1,2-a]pyridine (5d) 1 H MR (CDCl 3 ) 1E+9 1E+9 1E+9 1E+9 1E+9 9E+8 8E+8 7E+8 6E+8 5E+8 3E+8 1E+8-1E+8 39

.91 8.24 8.24 8.22 8. 7.5 7. 6.5 2.97 2.98 1.39 1. 8.2 8. 8.24 8.24 8.22 7.59 7.58 7.57 7.54 7.39 7.39 7.38 7.37 7.26 Chloro 6.95 6.95 6.93 6.92 6.9 6.9 7.8 6. 5.5 5. 4.5 7.6 7.4 7.2 7. 6.8 7.6 7.59 7.58 7.57 7.54 7.39 7.39 7.38 7.37 7.27 7.27 7.26 Chloroform-d 6.95 6.95 6.93 6.92 6.9 6.9 4. 8E+8 7E+8 6E+8 5E+8 3E+8 1E+8 3.5 3. 2.5 2. 1.5.86 1.6 1.57 1.55 1.53 1.51 1. 4.17 2-(cyclopropylethynyl)-3-(phenylethynyl)imidazo[1,2-a]pyridine (5d) 13 C MR (CDCl 3 ).93.92.91.91.5 1E+9 1E+9 1E+9 1E+9 9E+8 8E+8 7E+8 6E+8 5E+8 3E+8 1E+8-1E+8 4

144.59 14 13 12 11 132.89 131.53 128.92 128.6 126.78 125.14 122.55 117.47 113.6 111.31 1 11.48 99.54 9 8 7 77.16 Chloro 76.15 68.54 6 5 4 3 2 1 9.12.6 3-((4-methoxyphenyl)ethynyl)-2-(phenylethynyl)imidazo[1,2-a]pyridine (5e) 1 H MR (CDCl 3 ) -1 6E+8 6E+8 6E+8 5E+8 3E+8 1E+8 5E+7-5E+7 41

8.5 8. 7.5 7. 6.5 6. 5.5 5. 1. 3.2 2.39 4.11 3.35 8.4 8.2 8. 7.8 7.6 7.4 7.2 7. 6.8 6.6 8.27 8.26 8.25 8.24 8.24 7.64 7.62 7.61 7.6 7.59 7.56 7.53 7.36 7.34 7.32 7.32 7.3 7.29 7.29 7.27 7.26 Chloroform-d 6.96 6.94 6.94 6.92 6.92 6.9 6.89 8.27 8.26 8.25 8.24 8.24 7.62 7.56 7.53 7.36 7.34 6.96 6.96 6.94 6.94 6.92 6.92 6.9 6.89 3E+8 1E+8 5E+7 4.5 4. 3.28 3.5 3. H 3 C 2.5 O 2. 1.5 1..5. 3-((4-methoxyphenyl)ethynyl)-2-(phenylethynyl)imidazo[1,2-a]pyridine (5e) 13 C MR (CDCl 3 ) 6E+8 5E+8 3E+8 1E+8 5E+7-5E+7 42

16 16.3 15 144.66 14 13 12 11 133.45 133.18 131.96 131.68 128.83 128.43 126.93 125.22 122.72 117.56 114.29 113.7 112.33 1 12.6 94.49 9 8 82.41 77.16 Chloro 74.54 7 6 55.45 5 4 3 H 3 C O 2 1 2-phenyl-3-(phenylethynyl)imidazo[1,2-a]pyridine (6a) 1 H MR (CDCl 3 ) 8E+8 8E+8 7E+8 6E+8 6E+8 6E+8 5E+8 3E+8 1E+8 5E+7-5E+7 43

44..5 1. 1.5 2. 2.5 3. 3.5 4. 4.5 5. 5.5 6. 6.5 7. 7.5 8. 8.5-1E+8 1E+8 3E+8 5E+8 6E+8 7E+8 8E+8 9E+8 1E+9 1E+9 1E+9 1E+9 1E+9 1.1 1.34 4.29 2.25 2. 1. 2.78 6.93 6.93 6.95 6.96 6.98 6.98 7.26 Chloro 7.4 7.41 7.42 7.48 7.51 7.6 7.61 8.37 8.37 8.39 8.4 8.41 6.8 7. 7.2 7.4 7.6 7.8 8. 8.2 8.4 1E+8 3E+8 5E+8 6E+8 7E+8 8E+8 9E+8 1E+9 6.93 6.93 6.95 6.96 6.98 6.98 7.26 Chloroform-d 7.28 7.29 7.31 7.31 7.32 7.34 7.34 7.4 7.41 7.42 7.44 7.48 7.51 7.53 7.6 7.61 7.62 7.63 7.7 7.73 8.37 8.37 8.39 8.4 8.41 2-phenyl-3-(phenylethynyl)imidazo[1,2-a]pyridine (6a) 13 C MR (CDCl 3 )

147.81 145.19 14 13 12 133.33 131.38 128.9 128.78 128.72 127.42 126.65 125.31 122.78 117.54 113.28 11 14.85 1 11.44 9 8 7 78.24 77.16 Chloro 6 5 4 3 2 1 2-methyl-3-(phenylethynyl)imidazo[1,2-a]pyridine (6b) 1 H MR (CDCl 3 ) 5E+8 3E+8 1E+8 5E+7-5E+7 45

5 8..84 8.25 8.25 8.23 8.23 8.22 7.5 7. 6.5 6. 5.5 5. 4.5 4. 3.5 2.92 2.93 1.2 1. 8.2 8. 7.8 7.6 7.4 7.2 7. 6.8 8.25 8.25 8.25 8.23 8.23 8.22 7.57 7.56 7.56 7.54 7.54 7.53 7.39 7.37 7.26 Chloroform-d 7.24 7.24 7.22 7.22 7.21 7.21 7.19 7.19 6.9 6.89 6.87 6.87 6.85 7.56 7.56 7.54 7.54 7.37 6.9 6.89 6.87 6.87 6.85 6.85 1E+8 5E+7 3. 2.5 2.91 2.58 2. 1.5 1. CH 3.5. 2-methyl-3-(phenylethynyl)imidazo[1,2-a]pyridine (6b) 13 C MR (CDCl 3 ) 1E+9 1E+9 9E+8 8E+8 7E+8 6E+8 5E+8 3E+8 1E+8-1E+8 46

148.47 144.87 14 13 12 131.27 128.57 125.69 125.6 122.92 116.89 112.77 11 16.37 1 1.74 9 8 7 77.16 Chloro 76.86 6 5 4 CH 3 3 2 14.4 1 3-methyl-2-(phenylethynyl)imidazo[1,2-a]pyridine (6c) 1 H MR (CDCl 3 ) 2E+9 2E+9 1E+9 1E+9 1E+9 1E+9 1E+9 9E+8 8E+8 7E+8 6E+8 5E+8 3E+8 1E+8-1E+8 47

8. 7.5 7. 6.5 1.5 3.6 3.9 1.3 1. 8. 7.8 7.6 7.83 7.8 7.6 7.59 7.58 7.57 7.56 7.53 7.53 7.6 7.59 7.58 7.57 7.56 7.53 7.53 7.36 7.34 7.33 7.26 Chloro 6.87 6.87 6.85 6.85 6.83 6.82 6. 5.5 5. 4.5 7.4 7.2 7. 6.8 7.37 7.36 7.34 7.33 7.26 Chloroform-d 7.21 7.19 7.19 7.18 6.87 6.87 6.85 6.85 6.83 6.82 1E+8 5E+7 4. 3.5 3. 2.5 3. 2.59 2. 1.5 CH 3 1..5. 3-methyl-2-(phenylethynyl)imidazo[1,2-a]pyridine (6c) 13 C MR (CDCl 3 ) -.5 3E+8 1E+8 5E+7 48

144.48 14 13 12 131.74 128.45 126.46 124.4 123.78 123.25 122.95 117.74 112.76 11 1 92.73 9 83.7 8 7 77.16 Chloro 6 CH 3 5 4 3 2 1 9.18 2-(phenylethynyl)-3-(pyridin-4-yl)imidazo[1,2-a]pyridine (6d) 1 H MR (CDCl 3 ) 7E+8 6E+8 6E+8 6E+8 5E+8 3E+8 1E+8 5E+7-5E+7 49

9. 1.92 8.82 8.8 8.6.96 8.38 8.35 8.2 7.8 7.6 7.4 7.2 7. 6.6 1.93 1. 1.92 3.78 1. 7.77 7.75 7.69 7.65 7.53 7.52 7.51 7.5 7.36 7.34 7.34 7.3 7.26 Chloro 6.96 6.95 6.93 6.93 6.91 6.91 6.2 5.8 5.4 5. 4.6 4.2 3.8 3.4 2-(phenylethynyl)-3-(pyridin-4-yl)imidazo[1,2-a]pyridine (6d) 13 C MR (CDCl 3 ) 8E+8 8E+8 8E+8 7E+8 6E+8 6E+8 6E+8 5E+8 3E+8 1E+8 5E+7-5E+7 5

51-1 1 2 3 4 5 6 7 8 9 1 11 12 13 14 15-1E+8 1E+8 3E+8 5E+8 6E+8 7E+8 8E+8 9E+8 1E+9 77.16 Chloro 82.72 93.39 114.18 118.48 122.4 123.4 124.6 126.77 128.57 128.89 129.5 131.86 136.9 146.17 15.6